Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embolic Stroke of Undetermined Source (RESPECT ESUS)

Trial Profile

Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embolic Stroke of Undetermined Source (RESPECT ESUS)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Aspirin
  • Indications Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms RE-SPECT ESUS
  • Sponsors Boehringer Ingelheim; Unilfarma
  • Most Recent Events

    • 04 Apr 2016 Planned End Date changed from 1 Nov 2017 to 1 Jun 2018, according to ClinicalTrials.gov record.
    • 04 Apr 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Jun 2018, according to ClinicalTrials.gov record.
    • 15 Dec 2014 Planned number of patients changed from 6750 to 6000, according to a Boehringer Ingelheim media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top